Lycia Therapeutics IPO: revenue, losses and offering terms from its S-1
Lycia Therapeutics priced its IPO at $18 a share on 23 Oct 2026 and raised $318 million. Its shares trade on Nasdaq as LYCA. Revenue was $6.7 million in 2025, down 55% from 2024, with a net loss of $36.5 million.
Headlines
- Revenue, 2025
- $7M
- Down 55% on the year before
- Net loss, 2025
- $36M
- IPO price
- $18
- $318M raised
Lycia Therapeutics IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- LYCA
- IPO price
- $18
- Shares offered
- 17,640,000
- Raised
- $318M
- Registered
- $304M, the amount the filing fee is paid on
- Underwriters
- Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities
- First filed
- 5 Oct 2026
Lycia Therapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | $15M | - | -$27M |
| 2025 | $7M | -$41M | -$36M |
| First half of 2025 | $2M | - | - |
| First half of 2026 | - | -$21M | -$19M |
Lycia Therapeutics share structure and company facts
- Employees
- 31
- Headquarters
- South San Francisco, California
Lycia Therapeutics shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $18
- Priced 23 Oct 2026
- First close
- $30.00
- +67% on the IPO price
- Latest close
- $28.85
- +60% on the IPO price
Lycia Therapeutics' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Lycia Therapeutics' newest prospectus (424B4 filed 23 Oct 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.